SOUTH SAN FRANCISCO - Cytokinetics , Incorporated (NASDAQ:CYTK), a $5.7 billion biopharmaceutical company, has announced the awarding of $100,000 in grants to five patient advocacy organizations ...

Total of $100,000 Awarded to Five Patient Advocacy Organizationsto Support Communications and Community OutreachSOUTH SAN FRANCISCO, Calif., Jan.

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the ...

Cytokinetics, Inc. (CYTK) stock saw a modest uptick, ending the day at $50.75 which represents a slight increase of $2.89 or 6.04% from the prior close of $47.86. The stock opened at $47.75 and ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients. Stifel initiated coverage on ...

Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a ...

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Cytokinetics announced that it has begun enrolling patients in its mid-stage study of CK-4021586 (CK-586), a ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Sage Therapeutics was in focus after it rejected Biogen's acquisition proposal. Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding ...